Page last updated: 2024-12-05

2-ethylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Ethylpyridine is a heterocyclic compound with a pyridine ring substituted with an ethyl group at the 2-position. It is a colorless liquid with a pungent odor and is used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. 2-Ethylpyridine is typically synthesized by the alkylation of pyridine with ethyl bromide or ethyl chloride in the presence of a base, such as sodium hydroxide. It is also used as a catalyst in organic reactions, such as the Diels-Alder reaction. Studies on 2-ethylpyridine are conducted to investigate its reactivity, potential applications in synthesis, and its role as a building block for various complex molecules. '

2-ethylpyridine: RN given refers to compound with locant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7523
CHEMBL ID279305
SCHEMBL ID54892
MeSH IDM0146991

Synonyms (35)

Synonym
LS-13281
inchi=1/c7h9n/c1-2-7-5-3-4-6-8-7/h3-6h,2h2,1h
nsc964
pyridine, 2-ethyl-
.alpha.-ethylpyridine
100-71-0
2-ethylpyridine
nsc-964
2-ethylpyridine, 97%
alpha-ethylpyridine
einecs 202-881-9
nsc 964
CHEMBL279305
2-ethyl-pyridine
28631-77-8
E0168
ethylpyridine
AKOS000121053
A800262
pyridine, ethyl-
unii-06x1w46pyx
06x1w46pyx ,
FT-0612295
SCHEMBL54892
2-ethylpyridin
Q-100021
2-ethyl pyridine
DTXSID4021844
2-ethylpyridine, analytical standard
mfcd00006361
dimetindene maleate imp. a (ep); dimetindene imp. a (ep); 2-ethylpyridine; dimetindene maleate impurity a; dimetindene impurity a
Q27236227
AT23190
EN300-21760
Z113558650

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The present findings demonstrate the adverse effects of smoke constituents of mammalian reproduction and the differences in sensitivity to smoke components between male and female gametes."( In vitro assessment of reproductive toxicity of cigarette smoke and deleterious consequences of maternal exposure to its constituents.
Liu, M; Wu, SC, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Pyridines, which were the most abundant class of compounds identified, were purchased, assayed for purity, and tested in dose-response studies on hamster oviducts."( Pyridines in cigarette smoke inhibit hamster oviductal functioning in picomolar doses.
Arey, J; Iv, M; Riveles, K; Talbot, P,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1149238Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID30388Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30521Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -6 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (17.39)18.7374
1990's1 (4.35)18.2507
2000's6 (26.09)29.6817
2010's12 (52.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.87 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index46.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]